canada clinical guidance

Bipolar disorder: recognition, urgent risk, and shared-care monitoring

A Canadian clinical summary of bipolar disorder: recognition, urgent risk, and shared-care monitoring, with source-attributed priorities and explicit jurisdiction boundaries.

JurisdictionCanada
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceHealthcare professionals practising in Canada
This is an iatroX educational summary of named Canada sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.

Source and scope

This summary is bounded to the recommendations, population and decisions covered by CANMAT and ISBD 2018 guidelines for the management of patients with bipolar disorder. Apply it with the current provincial or territorial pathway where implementation differs.
sources for this section:CANMAT bipolar

Source-attributed clinical priorities

  • Assess mania, depression, mixed features, psychosis, suicide risk, substances and medical causes before selecting a phase-specific treatment.
  • Use CANMAT-ranked treatments for the current phase and maintenance history; avoid antidepressant monotherapy in bipolar I disorder.
  • Monitor metabolic, renal, thyroid, reproductive and medication-specific safety parameters and support relapse planning.
  • A longitudinal mood history and collateral information are essential because cross-sectional depression can obscure bipolarity.
sources for this section:CANMAT bipolar

Practical assessment and management workflow

1
Record current phase, sleep need, energy, impulsivity, psychosis, mixed features, functioning and immediate safety.
2
Review prior episodes, antidepressant activation, family history, substances and medical mimics.
3
Choose acute and maintenance treatment together, including psychotherapy, sleep regularity and a written relapse plan.
4
Monitor mood and function plus weight, metabolic, renal, thyroid or drug-level parameters specific to treatment.
sources for this section:CANMAT bipolar

Safety, red flags and urgent escalation

  • Urgent assessment is required for dangerous mania, severe depression, psychosis, catatonia or inability to care for self.
  • Discuss pregnancy and reliable contraception before teratogenic mood stabilizers.
  • Do not use antidepressant monotherapy for bipolar I depression.
sources for this section:CANMAT bipolar

Confirm the local pathway before acting

The evidence source is pan-Canadian, but formularies, funded access, referral routes, public-health directions and service availability remain provincial or territorial.
sources for this section:CANMAT bipolar

Source and implementation boundary

Read this educational summary with the linked source, current Canadian product information where medicines are involved, and the applicable provincial or territorial pathway. Local formularies, reporting duties, referral routes and service availability can differ.
sources for this section:CANMAT bipolar

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. Canadian Network for Mood and Anxiety TreatmentsCANMAT and ISBD 2018 guidelines for the management of patients with bipolar disorderaccessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Found a source update or regional discrepancy? Tell the iatroX editorial team.